Cheng Y - Search Results

1

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Jiang Z, et al. Among authors: cheng j, cheng y. Nat Med. 2024 Jan;30(1):249-256. doi: 10.1038/s41591-023-02677-x. Epub 2024 Jan 8. Nat Med. 2024. PMID: 38191615 Clinical Trial.

2

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.

Sun Y, Cheng Y, Hao X, Wang J, Hu C, Han B, Liu X, Zhang L, Wan H, Xia Z, Liu Y, Li W, Hou M, Zhang H, Xiu Q, Zhu Y, Feng J, Qin S, Luo X. Sun Y, et al. Among authors: cheng y. BMC Cancer. 2016 Apr 9;16:265. doi: 10.1186/s12885-016-2301-6. BMC Cancer. 2016. PMID: 27061082 Free PMC article. Clinical Trial.

3

[Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].

Li H, Liu Y, Liu Y, Liu J, Zhao D, Wang Y, Cheng Y. Li H, et al. Among authors: cheng y. Zhongguo Fei Ai Za Zhi. 2017 Nov 20;20(11):755-760. doi: 10.3779/j.issn.1009-3419.2017.11.06. Zhongguo Fei Ai Za Zhi. 2017. PMID: 29167005 Free PMC article. Chinese.

4

[Advances on Recognizing and Managing Tumor Heterogeneity].

Zhong R, Li H, Zhang S, Liu J, Cheng Y. Zhong R, et al. Among authors: cheng y. Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):712-718. doi: 10.3779/j.issn.1009-3419.2018.09.11. Zhongguo Fei Ai Za Zhi. 2018. PMID: 30201072 Free PMC article. Review. Chinese.

5

[Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients].

Li H, Yan S, Liu X, Liu Y, Ma L, Wang Y, Liu Y, Cheng Y. Li H, et al. Among authors: cheng y. Zhongguo Fei Ai Za Zhi. 2018 Nov 20;21(11):821-827. doi: 10.3779/j.issn.1009-3419.2018.11.03. Zhongguo Fei Ai Za Zhi. 2018. PMID: 30454543 Free PMC article. Chinese.

6

Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly.

Cheng Y, Wu L, Liu X, Zhao Y, Liu C, Chen Q, Sun T, Zheng Q. Cheng Y, et al. Medicine (Baltimore). 2019 Jan;98(3):e14136. doi: 10.1097/MD.0000000000014136. Medicine (Baltimore). 2019. PMID: 30653145 Free PMC article.

7

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.

Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, Hiraiwa M, Saito K, Funasaka S, Xu B. Yuan P, et al. Among authors: cheng y. Eur J Cancer. 2019 May;112:57-65. doi: 10.1016/j.ejca.2019.02.002. Epub 2019 Mar 29. Eur J Cancer. 2019. PMID: 30928806 Free article. Clinical Trial.

8

Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.

Cheng Y, Fan Y, Liu X, Liu Y, Liu J, Wang D, Yu Y, Qin S, Liu W, Huang C, Zhang H, Liang J, Shi J, Sheng L, Yu H. Cheng Y, et al. Oncol Lett. 2019 May;17(5):4701-4709. doi: 10.3892/ol.2019.10125. Epub 2019 Mar 8. Oncol Lett. 2019. PMID: 30988825 Free PMC article.

9

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Jiang Z, et al. Among authors: cheng y. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27. Lancet Oncol. 2019. PMID: 31036468 Clinical Trial.

10

Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.

Zhong R, Li H, Liu Y, Zhang S, Liu J, Huang Z, Cheng Y. Zhong R, et al. Among authors: cheng y. Thorac Cancer. 2020 Feb;11(2):456-460. doi: 10.1111/1759-7714.13286. Epub 2019 Dec 22. Thorac Cancer. 2020. PMID: 31865638 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27,272 results

Search Page